fda bpc-157 category 2 compounding 2023 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank An FDA advisory committee voted

An FDA advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8 6 votes (with The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like The Food and Drug Administration's committee on compounded drugs broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make. Follow the link FDA panel to review popular peptides amid persistent consumer appetite Reuters

SKU: 54086559348 · From cantondelareina.com.ar